Medicare GLP-1 Bridge rules: what to verify before choosing care

What changed

The Medicare GLP-1 Bridge is now active, and CMS updated its provider and pharmacy pages on July 13, 2026 with more operational detail. CMS launched the program on July 1, 2026, and Medicare.gov has beneficiary-facing coverage details for the $50 monthly copay, covered products, eligibility screening, provider steps, pharmacy information, and cost limits. CMS now also says the Bridge will be extended through December 31, 2027 because the BALANCE Model is not launching in 2027.

• Medicare.gov says eligible beneficiaries pay a $50 pharmacy copay for a 28- or 30-day monthly supply.
• The Bridge is nationwide, and Part D plans do not have to opt in for eligible beneficiaries to use it.
• Humana will serve as the single central processor for prior authorization, claims adjudication, and pharmacy payment.
• Patients should not assume a separate BALANCE Part D launch will replace the Bridge in 2027.
• CMS now spells out BMI-and-condition criteria, indication routing, pharmacy claim steps, and limits on fills and pen-needle coverage.

Why this matters when comparing providers

The Bridge could change the practical questions a Medicare Part D beneficiary asks a clinic, but it does not make provider quality, licensing, follow-up, or medication sourcing questions less important. A clinic still needs to explain who evaluates the patient, who submits paperwork, how prescriptions are coordinated, and what happens if the Bridge is not available for the patient's situation.

Ask who handles prior authorization now that the program is live

CMS says access requires a medical provider to send a prescription to the pharmacy and complete a prior authorization request when requested. CMS strongly encourages electronic prior authorization, says the pharmacy will usually send the PA request to the prescriber within 24 to 72 hours after a Bridge claim indicates PA is required, and says prescribers can use the fax form themselves if no request arrives after 72 hours. Patients should ask a clinic whether it actually supports that workflow before relying on a Bridge price estimate.

• Will the provider submit Bridge prior authorization requests electronically or by fax?
• Will the provider explain what criteria they can and cannot attest to?
• Who checks whether the pharmacy sent the PA request back to the prescriber within 24 to 72 hours?
• Who follows up if the pharmacy or central processor requests more information?
• How will the clinic communicate approvals, denials, missing information, or pharmacy claim problems?

Know what has to happen at the pharmacy

CMS pharmacy guidance says Bridge claims use a dedicated BIN and PCN, and that pharmacies need the beneficiary's Medicare Beneficiary Identifier to submit a claim. CMS also says a Part D denial is not required before a Bridge claim if the prescriber has determined the patient might be eligible and directs the pharmacist to send the claim to the Bridge. The PA fax form separately says a denied claim to the Bridge BIN and PCN must exist before the prescriber submits the PA request, so the practical question is whether the clinic and pharmacy know which denial or request starts the PA workflow.

• Bridge BIN and PCN: 028918 and MEDDGLP1BR.
• Ask which pharmacy will process the claim and whether it understands the Bridge pathway.
• Ask how the prescriber and pharmacy decide whether a claim should go to ordinary Part D or directly to the Bridge.
• Ask what happens if the pharmacy cannot process the Bridge claim, needs the Medicare Beneficiary Identifier, or receives a PA-related reject code.

Separate Bridge coverage from Part D coverage

CMS says the Bridge is for eligible GLP-1 drugs when prescribed to reduce excess body weight and maintain weight reduction for beneficiaries who meet the demonstration criteria. Medicare.gov says people who already get GLP-1 drugs through Medicare Part D, or who have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, are not eligible for the Bridge because those uses may belong under ordinary Part D coverage. CMS also says a prescription intended to reduce major adverse cardiovascular event risk should be routed to the Part D plan rather than the Bridge. Part D plan guidance says CMS will review 2026 utilization data when checking whether a beneficiary previously received a GLP-1 through Part D, and CMS has not yet determined the 2027 lookback period. Patients should ask both the provider and plan which pathway applies before relying on a price estimate.

Ask how the clinic applies the clinical criteria

CMS says the prescriber must attest that the beneficiary met Bridge clinical criteria at the time GLP-1 therapy was initiated, including age, BMI, weight-management use, ongoing lifestyle modification, and specified conditions for some BMI ranges. That means a current BMI alone may not answer the eligibility question. A provider should be able to explain what history, diagnosis, medication-use, and documentation details it needs without promising that CMS or the central processor will approve coverage.

• Which BMI-and-condition criterion is the provider evaluating?
• Does the provider use the BMI at therapy initiation or only today's BMI?
• Which documentation will the provider keep if CMS or the central processor asks for support?

Check the product and pharmacy path

CMS and Medicare.gov currently list Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen as eligible products for the Bridge, while noting the product list may change. CMS says Zepbound single-dose vial and single-dose pen formulations are not available through the Bridge, pen needles for Zepbound KwikPen are not covered, and Bridge fills are limited to a single 28- or 30-day monthly supply rather than 60- or 90-day fills. The pharmacy page also says coupons and discount programs may not be applied to Bridge claims.

• Which product is the clinician discussing, and why?
• Which formulation and pharmacy claim path apply?
• Does the patient need to buy any supplies separately, such as pen needles?
• What happens if the product, formulation, monthly fill, pharmacy, or claim path is not available?

Compare the whole care model, not just the copay

A $50 Bridge copay does not answer every cost question. Medicare.gov says the Bridge copay does not count toward the Part D deductible or out-of-pocket limit, cannot be lowered by Extra Help, and cannot be spread through the Medicare Prescription Payment Plan. Clinics may still charge for visits, memberships, labs, follow-up, nutrition support, insurance paperwork, messaging, or cancellation. The better comparison is the full first-90-day cost and the plan for ongoing monitoring if a licensed clinician decides treatment is appropriate.

What to ask before choosing a clinic

Use the Bridge as a reason to ask more precise questions, not fewer. A clinic that advertises Medicare GLP-1 help should be able to explain eligibility screening, documentation, pharmacy routing, denial handling, and follow-up without promising coverage or treatment.

• Do you support Bridge prior authorization, or do you only prescribe if my plan already covers the drug?
• Who checks whether my use belongs under the Bridge or ordinary Part D?
• How do you document side effects, refill delays, coverage denials, and pharmacy problems after the first fill?

What remains uncertain

CMS says the product list and operational details may be updated over the demonstration period, and it has not yet determined the 2027 lookback period for prior Part D GLP-1 use. Patients should avoid treating early marketing language as a guarantee and should verify details with the clinic, plan, pharmacy, Medicare, and a licensed clinician before paying.